"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Clinician Information:
Teslascan Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Teslascan 0.01 mmol/ml solution for infusion (mangafodipir) is a contrast medium used for for diagnostic Magnetic Resonance Imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. It is also used as an adjunct to MRI to aid in the investigation of focal pancreatic lesions. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include warmth/flushing, headache and nausea.
The recommended adult dose of Teslascan is 0.5 ml/kg bodyweight (5 μmol/kg bodyweight). Teslascan may interact with other drugs. Tell your doctor all medications and supplements you use. Teslascan must not be used during pregnancy. Tell your doctor if you are pregnant before receiving Teslascan. It is unknown how much of this drug may pass into breast milk. Breastfeeding should be discontinued from the time of administration and should not be recommenced until 14 days after administration of Teslascan. Consult your doctor before breastfeeding.
Our Teslascan 0.01 mmol/ml solution for infusion (mangafodipir) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Teslascan FDA Prescribing Information: Side Effects
Most of the adverse reactions reported were transient and of mild intensity. Those most commonly reported were: feeling of warmth/flushing, headache and nausea. In clinical trials with Teslascan (mangafodipir) , adverse reactions have been reported with the following frequencies given in the table below (very common ≥ 1/10; common ( ≥ 1/100 to < 1/10); uncommon ( ≥ 1/1,000 to < 1/100); rare ( ≥ 1/10,000 to < 1/1,000); very rare < 1/10,000, not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
|System Organ Class||Adverse Reactions||Frequency|
|Immune system disorders||Hypersensitivity reactions (such as skin reactions, rhinitis, pharyngitis)
|Nervous system disorders||Headache
Dizziness, paraesthesia, transient perverted sensation of taste
|Eye disorders||Visual disturbance||Very rare|
Abdominal pain, diarrhoea, vomiting
|General disorders and administration site conditions||Flushing, feeling hot
Fever, injection site pain
Mangafodipir can cause transient increases of bilirubin and liver transaminases and transient decreases in plasma zinc.
The frequency of mild and moderate, non-serious adverse reactions, mainly transient warmth and flushing, is likely to increase when TESLASCAN (mangafodipir) is administered at the faster rate advised (4-6 ml/min).
Read the entire FDA prescribing information for Teslascan (Mangafodipir) »
Additional Teslascan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.